home / stock / crnx / crnx news

CRNX News and Press, Crinetics Pharmaceuticals Inc. From 09/03/19

Stock Information
Company Name: Crinetics Pharmaceuticals Inc.
Stock Symbol: CRNX
Market: NASDAQ
Website: crinetics.com
Menu
CRNX CRNX Quote CRNX Short CRNX News CRNX Articles CRNX Message Board
Get CRNX Alerts

News, Short Squeeze, Breakout and More Instantly...
CRNX - Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced t...
CRNX - Crinetics Pharmaceuticals EPS misses by $0.05

Crinetics Pharmaceuticals (NASDAQ: CRNX ): Q2 GAAP EPS of -$0.51 misses by $0.05 . More news on: Crinetics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

CRNX - Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported fin...

CRNX - Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism

SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced t...
CRNX - Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors

SAN DIEGO, July 16, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced th...

CRNX - Crinetics Pharmaceuticals begins early-stage study of CRN01941 for NETs

Crinetics Pharmaceuticals (NASDAQ: CRNX ) has initiated Phase 1, placebo-controlled, single- and multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CRN01941 in healthy volunteers. More news on: Crinetics Pharmaceuticals, Inc., Healthcare stocks news, ...

CRNX - Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors

SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced th...
CRNX - Crinetics Pharmaceuticals reports Q1 results

Crinetics Pharmaceuticals (NASDAQ: CRNX ): Q1 GAAP EPS of -$0.37. More news on: Crinetics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

CRNX - Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported fina...

CRNX - Crinetics doses first patients in phase 2 clinical trials of CRN00808

Crinetics Pharmaceuticals (NASDAQ: CRNX ) begins patients dosing in the ACROBAT EVOLVE and EDGE trials for CRN00808 in patients with acromegaly. More news on: Crinetics Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Previous 10 Next 10